

September 2004

## **Review of 714X by the Cancer Working Group of the National Advisory Council for Complementary and Alternative Medicine**

The Cancer Working Group met on September 9, 2004 to review data on 714X that was provided by CERBE Distribution, Inc. of Quebec, Canada. The purpose of the meeting was to determine whether the data presented warranted further research on this product in preclinical or early phase clinical trials in cancer patients. The product was submitted for review through the National Cancer Institute's Best Case Series, which is a process for evaluation of data from alternative medicine practitioners.

After careful deliberation, the Cancer Working Group determined that:

- it is premature at this time to recommend studies of 714X
- the theoretical basis for use of 714X to boost the immune system, and the evidence to support this theory, is weak
- 714X is not ready for randomized controlled clinical trials in cancer patients.

At the Cancer Working Group meeting, several cancer patients testified as to their experience in using 714X. While these patient case studies are compelling life experiences, they are not scientific evidence of the effectiveness of 714X.

The Cancer Working Group recommended that the manufacturer of 714X take the following steps:

- have results of ongoing studies in Canada published in a peer-reviewed scientific journal
- work with experienced researchers to submit a grant application to study 714X in an animal model.

The National Center for Complementary and Alternative Medicine will consider funding investigator-initiated grant applications for research on 714X that are found to be highly meritorious through the NIH peer review process.

Further information:

- [PDQ statement](#)
- [Request for Cases](#)